Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Jan. 12, 2026 Weight-loss drugs like Ozempic and Wegovy are changing how Americans spend money on food. A large Cornell study found households cut grocery spending by over 5% within six months, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback